Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1998 1
2000 2
2005 1
2011 1
2017 1
2019 1
2020 1
2021 49
2022 557
2023 83

Text availability

Article attribute

Article type

Publication date

Search Results

593 results

Results by year

Filters applied: . Clear all
Page 1
Assessment of Cardiovascular Disease Risk: A 2022 Update.
Goldsborough E 3rd, Osuji N, Blaha MJ. Goldsborough E 3rd, et al. Endocrinol Metab Clin North Am. 2022 Sep;51(3):483-509. doi: 10.1016/j.ecl.2022.02.005. Epub 2022 Jul 4. Endocrinol Metab Clin North Am. 2022. PMID: 35963625 Review.
ASCVD risk assessment begins with the use of a traditional 10-year risk calculator, with further refinement through the consideration of risk-enhancing factors (particularly lipoprotein(a)) and subclinical atherosclerosis testing (particularly coronary artery calcium (CAC) …
ASCVD risk assessment begins with the use of a traditional 10-year risk calculator, with further refinement through the consideration of ris …
Lp(a): a New Pathway to Target?
Nurmohamed NS, Kraaijenhof JM, Stroes ESG. Nurmohamed NS, et al. Curr Atheroscler Rep. 2022 Nov;24(11):831-838. doi: 10.1007/s11883-022-01060-4. Epub 2022 Sep 6. Curr Atheroscler Rep. 2022. PMID: 36066785 Free PMC article. Review.
RECENT FINDINGS: As Lp(a) levels are determined genetically, lifestyle interventions have no effect on Lp(a)-mediated ASCVD risk. While traditional low-density lipoprotein cholesterol (LDL-C) can now be effectively lowered in the vast majority of patients, cu …
RECENT FINDINGS: As Lp(a) levels are determined genetically, lifestyle interventions have no effect on Lp(a)-mediated ASCVD ri …
Lipoprotein(a) and its Significance in Cardiovascular Disease: A Review.
Duarte Lau F, Giugliano RP. Duarte Lau F, et al. JAMA Cardiol. 2022 Jul 1;7(7):760-769. doi: 10.1001/jamacardio.2022.0987. JAMA Cardiol. 2022. PMID: 35583875 Review.
IMPORTANCE: Lipoprotein(a) (Lp[a]) is a low-density lipoprotein (LDL) cholesterol-like particle bound to apolipoprotein(a). ...These findings have led to the formulation of the Lp(a) hypothesis, namely that Lp(a) lowering leads to cardiovascular …
IMPORTANCE: Lipoprotein(a) (Lp[a]) is a low-density lipoprotein (LDL) cholesterol-like particle bound to apolipoprotein …
A Modern Approach to Dyslipidemia.
Berberich AJ, Hegele RA. Berberich AJ, et al. Endocr Rev. 2022 Jul 13;43(4):611-653. doi: 10.1210/endrev/bnab037. Endocr Rev. 2022. PMID: 34676866 Free PMC article.
With regard to cardiovascular disease, elevated low-density lipoprotein cholesterol is essentially causal, and clinical practice guidelines worldwide have recommended treatment thresholds and targets for this variable. Furthermore, recent studies have established elevated …
With regard to cardiovascular disease, elevated low-density lipoprotein cholesterol is essentially causal, and clinical practice guid …
Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement.
Kronenberg F, Mora S, Stroes ESG, Ference BA, Arsenault BJ, Berglund L, Dweck MR, Koschinsky M, Lambert G, Mach F, McNeal CJ, Moriarty PM, Natarajan P, Nordestgaard BG, Parhofer KG, Virani SS, von Eckardstein A, Watts GF, Stock JK, Ray KK, Tokgözoğlu LS, Catapano AL. Kronenberg F, et al. Eur Heart J. 2022 Oct 14;43(39):3925-3946. doi: 10.1093/eurheartj/ehac361. Eur Heart J. 2022. PMID: 36036785 Free PMC article.
This 2022 European Atherosclerosis Society lipoprotein(a) [Lp(a)] consensus statement updates evidence for the role of Lp(a) in atherosclerotic cardiovascular disease (ASCVD) and aortic valve stenosis, provides clinical guidance for testing and treatin …
This 2022 European Atherosclerosis Society lipoprotein(a) [Lp(a)] consensus statement updates evidence for the role of …
Lipoprotein(a): A Genetically Determined, Causal, and Prevalent Risk Factor for Atherosclerotic Cardiovascular Disease: A Scientific Statement From the American Heart Association.
Reyes-Soffer G, Ginsberg HN, Berglund L, Duell PB, Heffron SP, Kamstrup PR, Lloyd-Jones DM, Marcovina SM, Yeang C, Koschinsky ML; American Heart Association Council on Arteriosclerosis, Thrombosis and Vascular Biology; Council on Cardiovascular Radiology and Intervention; and Council on Peripheral Vascular Disease. Reyes-Soffer G, et al. Arterioscler Thromb Vasc Biol. 2022 Jan;42(1):e48-e60. doi: 10.1161/ATV.0000000000000147. Epub 2021 Oct 14. Arterioscler Thromb Vasc Biol. 2022. PMID: 34647487 Free PMC article. Review.
High levels of lipoprotein(a) [Lp(a)], an apoB100-containing lipoprotein, are an independent and causal risk factor for atherosclerotic cardiovascular diseases through mechanisms associated with increased atherogenesis, inflammation, and thrombosis. ...The 2 …
High levels of lipoprotein(a) [Lp(a)], an apoB100-containing lipoprotein, are an independent and causal risk factor for …
Elevated Lipoprotein(a) and Risk of Atrial Fibrillation: An Observational and Mendelian Randomization Study.
Mohammadi-Shemirani P, Chong M, Narula S, Perrot N, Conen D, Roberts JD, Thériault S, Bossé Y, Lanktree MB, Pigeyre M, Paré G. Mohammadi-Shemirani P, et al. J Am Coll Cardiol. 2022 Apr 26;79(16):1579-1590. doi: 10.1016/j.jacc.2022.02.018. J Am Coll Cardiol. 2022. PMID: 35450575 Free PMC article.
However, preventative therapies are needed with ancillary benefits on its cardiovascular comorbidities. Lipoprotein(a) (Lp[a]) is a recognized risk factor for atherosclerotic cardiovascular disease (ASCVD), which itself increases AF risk, but it remains unknown whet …
However, preventative therapies are needed with ancillary benefits on its cardiovascular comorbidities. Lipoprotein(a) (Lp[a]) …
Small Interfering RNA to Reduce Lipoprotein(a) in Cardiovascular Disease.
O'Donoghue ML, Rosenson RS, Gencer B, López JAG, Lepor NE, Baum SJ, Stout E, Gaudet D, Knusel B, Kuder JF, Ran X, Murphy SA, Wang H, Wu Y, Kassahun H, Sabatine MS; OCEAN(a)-DOSE Trial Investigators. O'Donoghue ML, et al. N Engl J Med. 2022 Nov 17;387(20):1855-1864. doi: 10.1056/NEJMoa2211023. Epub 2022 Nov 6. N Engl J Med. 2022. PMID: 36342163 Free article. Clinical Trial.
BACKGROUND: Lipoprotein(a) is a presumed risk factor for atherosclerotic cardiovascular disease. ...RESULTS: Among the 281 enrolled patients, the median concentration of lipoprotein(a) at baseline was 260.3 nmol per liter, and the median concentration of low-density …
BACKGROUND: Lipoprotein(a) is a presumed risk factor for atherosclerotic cardiovascular disease. ...RESULTS: Among the 281 enrolled p …
Frequent questions and responses on the 2022 lipoprotein(a) consensus statement of the European Atherosclerosis Society.
Kronenberg F, Mora S, Stroes ESG, Ference BA, Arsenault BJ, Berglund L, Dweck MR, Koschinsky ML, Lambert G, Mach F, McNeal CJ, Moriarty PM, Natarajan P, Nordestgaard BG, Parhofer KG, Virani SS, von Eckardstein A, Watts GF, Stock JK, Ray KK, Tokgözoğlu LS, Catapano AL. Kronenberg F, et al. Atherosclerosis. 2023 Jun;374:107-120. doi: 10.1016/j.atherosclerosis.2023.04.012. Epub 2023 Apr 28. Atherosclerosis. 2023. PMID: 37188555 Free article. Review.
In 2022, the European Atherosclerosis Society (EAS) published a new consensus statement on lipoprotein(a) [Lp(a)], summarizing current knowledge about its causal association with atherosclerotic cardiovascular disease (ASCVD) and aortic stenosis. ...This revi …
In 2022, the European Atherosclerosis Society (EAS) published a new consensus statement on lipoprotein(a) [Lp(a)], summ …
Coronary heart disease risk: Low-density lipoprotein and beyond.
Shaya GE, Leucker TM, Jones SR, Martin SS, Toth PP. Shaya GE, et al. Trends Cardiovasc Med. 2022 May;32(4):181-194. doi: 10.1016/j.tcm.2021.04.002. Epub 2021 Apr 17. Trends Cardiovasc Med. 2022. PMID: 33872757 Review.
Great advances have been made in elucidating the complex mechanistic interactions among risk factors associated with CHD, yielding abundant success towards preventive measures and the development of pharmaceuticals to prevent and treat CHD via attenuation of lipoprotein-me …
Great advances have been made in elucidating the complex mechanistic interactions among risk factors associated with CHD, yielding abundant …
593 results